TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33849723
Drug: Typhim Vi®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhim Vi® (Vi polysaccharide vaccine)
Study: 33289785
Drug: ACT on
Normalized name: Liver extract only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT on Health program plus weekly phone coaching
Study: 34982866
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure (PE) therapy for PTSD
Study: 33079570
Drug: Direct-acting oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting oral anticoagulants (DOACs)
Study: 33314313
Drug: Active vibration
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vibration therapy (30 Hz and 0.3 g)
Study: 34480773
Drug: Imaginal exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaginal exposure therapy
Study: 35057755
Drug: Tablet-assisted motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-assisted motivational counselling at the participant's home and two follow-up telephone sessions
Study: 35057755
Drug: Tablet-assisted motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-assisted motivational counselling
Study: 34222044
Drug: HA-L vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-L vaccine
Study: 34222044
Drug: HA-I vaccine
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-I vaccine
Study: 32282927
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) performed by trained general interventional radiologists
Study: 32282927
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) with aspiration and stent retrievers introduced in 2012
Study: 32282927
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) in 2018
Study: 33247344
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for 3 months
Study: 33046213
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of the dopaminergic antagonist amisulpride
Study: 35657611
Drug: Disease Modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease Modifying Anti-Rheumatic Drugs (DMARDs)
Study: 38552197
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2
Study: 32563863
Drug: DHA-enriched fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched fish oil (FO) 2 g/day (860 mg DHA + 120 mg EPA)
Study: 35440345
Drug: Mass Prolonged
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Prolonged Exposure (MPE) therapy
Study: 35440345
Drug: Standard Prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Prolonged Exposure (SPE) therapy
Study: 33904589
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to attachment‐based family therapy (ABFT)
Study: 33904589
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to family‐enhanced nondirective supportive therapy (FE‐NST)
Study: 33904589
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to attachment‐based family therapy (ABFT) with therapeutic alliance as a moderator
Study: 33904589
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to family‐enhanced nondirective supportive therapy (FE‐NST) with therapeutic alliance as a moderator
Study: 34429646
Drug: Lidocaine topical
Normalized name: lidocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine topical system 1.8% under swimming conditions
Study: 34429646
Drug: Lidocaine topical
Normalized name: lidocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine topical system 1.8% under showering conditions
Study: 32606902
Drug: Lidocaine topical
Normalized name: lidocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine topical system 1.8% under normal conditions
Study: 33654425
Drug: Lidocaine topical
Normalized name: lidocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine topical system 1.8%
Study: 32293533
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) control group (n = 40)
Study: 37676282
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitors (PPI)
Study: 38249330
Drug: Cetuximab monotherapy
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab monotherapy
Study: 32909356
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) by washed preparation
Study: 32931950
Drug: Basophil activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basophil activation test (BAT) using shrimp extract as stimulant
Study: 33438008
Drug: Ozanimod HCl
Normalized name: ozanimod HCl
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ozanimod HCl 1 mg daily
Study: 35195913
Drug: Intravenous liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous liposomal irinotecan at 70 mg/m2
Study: 32759848
Drug: EAT: Eating
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAT: Eating As Treatment intervention
Study: 34543246
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anesthesia (TIVA group)
Study: 35075551
Drug: Periarticular infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular infiltration of low-dose dexamethasone
Study: 35075551
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dexamethasone
Study: 35021269
Drug: DS-1211 (3-3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1211 (3-3000 mg single dose)
Study: 33333200
Drug: Conventional Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional Radiation Therapy (cRT) - 1 × 8 Gy, 5 × 4 Gy, or 10 × 3 Gy
Study: 34091914
Drug: Stereotactic Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic Body Radiation Therapy (SBRT)
Study: 32769914
Drug: NBP injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBP injection
Study: 33290108
Drug: Dashboard driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dashboard driven infliximab dosing (precision group, PG)
Study: 33290108
Drug: Standard infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard infliximab dosing (control group, CG)
Study: 35131978
Drug: Balance training
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance training added to physical therapy
Study: 35131978
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (control group)
Study: 36440473
Drug: Intrathecal drug
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal drug delivery (IDD)
Study: 36440473
Drug: Intrathecal compounded
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal compounded medications
Study: 33346899
Drug: Surface treatment
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface treatment group
Study: 33346899
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (TXA by intravenous drip combined with local injection into the articular cavity)
Study: 33080291
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine
Study: 32150549
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 6 weeks
Study: 33938071
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group (HDM immunotherapy)
Study: 33938071
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group (HDM immunotherapy) in younger individuals (16-30 years)
Study: 32895353
Drug: Intra articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra articular Hyaluronic acid injections weekly for three weeks
Study: 36942062
Drug: Enoxaparin 60
Normalized name: enoxaparin 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 60 mg daily
Study: 36942062
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg daily (Control)
Study: 36136263
Drug: Microfracture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfracture treatment
Study: 33323326
Drug: Intensive individualized
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive individualized nutrition counseling (3 monthly sessions)
Study: 34379777
Drug: Error-Augmentation Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error-Augmentation Training (EAT)
Study: 32648392
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group
Study: 35742573
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for cannabis cessation (CBT-CC)
Study: 34453620
Drug: Ultra-low tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low tidal volume ventilation (3 ml/kg predicted body weight)
Study: 34453620
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation (6 ml/kg predicted body weight)
Study: 35238225
Drug: D-bread (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-bread (50 g/day, fortified with 1000 IU of vitamin D)
Study: 35238225
Drug: D-supplement (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-supplement (1000 IU vitamin D)
Study: 35238225
Drug: P-yogurt (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-yogurt (500 mL/day, plain yogurt)
Study: 35152197
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by concurrent chemoradiotherapy
Study: 37745479
Drug: High-dose propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose propofol
Study: 33475663
Drug: Polymethoxyflavone purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymethoxyflavone purified from Kaempferia parviflora (12 mg per day for 12 weeks)
Study: 39185955
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus Aspirin 100 mg once daily
Study: 33357465
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g bolus, followed by continuous infusion of 1 g every 8 h, terminated immediately before aneurysm treatment, or 24 h after start of the medication)
Study: 33879015
Drug: Isotonic intravenous
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic intravenous fluid (sodium chloride, 0.9%, and dextrose, 5%)
Study: 33879015
Drug: Hypotonic intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic intravenous fluid (sodium chloride, 0.15%, and dextrose, 5%)
Study: 32926462
Drug: Baricitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (all doses)
Study: 32134754
Drug: Fixation time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixation time of 96 hours with SP142 antibody
Study: 32134754
Drug: Fixation time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixation time of 96 hours with SP263 antibody
Study: 32134754
Drug: SP142 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP142 antibody after 96 hours of fixation
Study: 32134754
Drug: SP263 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP263 antibody after 96 hours of fixation
Study: 34142567
Drug: Isotonic seawater
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic seawater spray containing chamomile liquid extract (Group A)
Study: 34142567
Drug: Isotonic seawater
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic seawater spray (Group B)
Study: 32618258
Drug: Preventive zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive zinc (PZ) tablets (7 mg/day)
Study: 32618258
Drug: Therapeutic zinc
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic zinc (TZ) supplements for diarrhea treatment (20 mg/day for 10 days)
Study: 32618258
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (MNP; containing 10 mg zinc and 14 other micronutrients)
Study: 34290965
Drug: Saffron (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (100 mg/day)
Study: 32963047
Drug: Romilkimab 200
Normalized name: Romilkimab
DrugBank: Romilkimab (DB16318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romilkimab 200 mg subcutaneously once a week for 24 weeks
Study: 38537780
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg twice daily
Study: 32691672
Drug: BIOF2 (bioactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIOF2 (bioactive cell-free formulation)
Study: 32271146
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual treatment)
Study: 35063205
Drug: LCω3 (MAG‐EPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCω3 (MAG‐EPA 3 g daily)
Study: 33094551
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 - 17% EDTA, Saline and 2% Chlorhexidine solution
Study: 34499174
Drug: Multicomponent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent treatment (pain neuroscience education, therapeutic exercise, cognitive behavioral therapy, and mindfulness, delivered in 2-hour weekly sessions for 12 weeks)
Study: 34499174
Drug: Multicomponent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent treatment
Study: 34499174
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (mainly pharmacological treatment)
Study: 32391579
Drug: DFMO maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO maintenance therapy for HRNB after standard COG induction, consolidation and immunotherapy for 2 years
Study: 32391579
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (76 HRNB patients treated at Beat Childhood Cancer Research Consortium hospitals, disease-free after standard therapy, no DFMO)
Study: 34283997
Drug: 12-month, individually
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month, individually tailored, progressive, physiotherapist-supervised physical exercise twice a week (n=150)
Study: 34851734
Drug: Fentanyl (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (75 µg)
Study: 32197936
Drug: PSA-based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA-based screening (two rounds at 4-6 year intervals, biopsy recommended if PSA>=3.0 ng/mL)
Study: 35355827
Drug: Neutral Sodium
Normalized name: Neutral Sodium Fluoride Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral Sodium Fluoride (NaF) oral rinse (Colgate® PreviDent® Dental Rinse‐0.2% NaF) weekly for 6 months
Study: 35355827
Drug: Acidulated Phosphate
Normalized name: Acidulated Phosphate Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidulated Phosphate Fluoride (APF) oral rinse (Colgate® Ortho Defense@ PhosFlur® Rinse‐0.044% w/v of NaF) daily for 6 months
Study: 34147154
Drug: Dihydroartemisinin-piperaquine mass
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine mass drug administration (MDA) with a target total dose of 7 mg/kg dihydroartemisinin and 55 mg/kg piperaquine, delivered in three rounds over a period from March 4 to May 10, 2015.
Study: 34028126
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus Capecitabine (L + C)
Study: 33267723
Drug: Antihypertensive medications
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medications
Study: 34548312
Drug: Procalcitonin guided
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin guided antibiotics (n=195)
Study: 32331005
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (56 mg or 84 mg) in combination with newly initiated oral antidepressant (ESK+AD)
Study: 32331036
Drug: Oral antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidepressant + placebo nasal spray (AD+PBO)
Study: 35413861
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment thrice weekly for 4 weeks
Study: 34881911
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT)
Study: 33833507
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate (GLY) 25 µg twice-daily (BID)
Study: 33833507
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate (GLY) 25 µg BID
Study: 32410424
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia (MA) therapy including oral administration of celecoxib before operation, local anesthetic wound infiltration during operation, and ice compression and oral administration of celecoxib after operation.
Study: 32410424
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia (MA) therapy.
Study: 32410424
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia pump (Control group).
Study: 37045683
Drug: 2 +
Normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 + 1 schedule (two primary doses and a booster)
Study: 37045683
Drug: 1 +
Normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 + 1 schedule (doses at 3 and 12 months)
Study: 36316932
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nicotinamide 5 times a day for 2 days
Study: 35315603
Drug: Viread® (tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viread® (tenofovir disoproxil fumarate) at a dose of 300 mg once daily for 48 weeks
Study: 34459996
Drug: Daily Intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Intake of Metals (DIM) and Target Hazard Quotient (THQ)
Study: 37465817
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: 34193504
Drug: Bromocriptine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (10 mg/day and 22.5 mg/day)
Study: 38485487
Drug: Inhaled Nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide (NO)
Study: 33933036
Drug: Ambulatory oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory oxygen therapy
Study: 32687695
Drug: Sitafloxacin granules
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin granules 50 mg single dose
Study: 32687695
Drug: Sitafloxacin granules
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin granules 100 mg single dose
Study: 32687695
Drug: Sitafloxacin granules
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin granules 200 mg single dose
Study: 37394178
Drug: EpiPen (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EpiPen (0.3 mg)
Study: 34332429
Drug: Integrated Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Coping Awareness Therapy (I-CAT)
Study: 33546045
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin Pill combined with Western medicine
Study: 32768182
Drug: Fully guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully guided protocol (24 implants)
Study: 32501868
Drug: OPRX-106 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPRX-106 2 mg administered orally once daily for 8 weeks
Study: 32546198
Drug: Systematic HRQoL
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic HRQoL assessment using the CHES software before each consultation coupled with therapeutic information (three workshops related to understanding the prescription, nutrition, and fatigue)
Study: 36042217
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop insulin delivery system
Study: 38985461
Drug: Edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 30 mg once daily